SUMMIT THERAPEUTICS LIMITED
Get an alert when SUMMIT THERAPEUTICS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-10-03 (in 5mo)
Last made up 2025-09-19
Watchouts
Cash
£313K
-30.5% vs 2023
Net assets
£608K
-83.2% vs 2023
Employees
0
Average over period
Profit before tax
-£3M
+30.5% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
Until additional funding is secured, these circumstances cast significant doubt upon the ability of the Group to continue to support the Company to meet its liabilities as they fall due, which in turn indicates the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.
Name history
Renamed 4 times since incorporation
- SUMMIT THERAPEUTICS LIMITED 2020-09-18 → present
- SUMMIT THERAPEUTICS PLC 2015-02-19 → 2020-09-18
- SUMMIT CORPORATION PLC 2007-07-19 → 2015-02-19
- VASTOX PLC 2004-09-30 → 2007-07-19
- COBRADRAGON PUBLIC LIMITED COMPANY 2004-08-04 → 2004-09-30
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | -£4,360,213 | -£3,030,985 | |
| Profit before tax | -£4,360,213 | -£3,030,985 | |
| Net profit | -£4,360,213 | -£3,030,985 | |
| Cash | £450,760 | £313,283 | |
| Total assets less current liabilities | £3,624,595 | £608,154 | |
| Net assets | £3,624,595 | £608,154 | |
| Equity | £3,624,595 | £608,154 | |
| Average employees | 0 | 0 | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Return on capital employed | -120.3% | -498.4% | |
| Gearing (liabilities / total assets) | 2.9% | 25.4% | |
| Current ratio | 7.40x | 3.59x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“Until additional funding is secured, these circumstances cast significant doubt upon the ability of the Group to continue to support the Company to meet its liabilities as they fall due, which in turn indicates the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.”
Group structure
- SUMMIT THERAPEUTICS LIMITED · parent
- Summit (Oxford) Limited 100%
- Discuva Limited 100%
Significant events
- “During the year ended 31 December 2023, Summit Discovery 1 Limited, Summit Corporation Employee Benefit Trust Company Limited, Summit (Cambridge) Limited, Summit (Wales) Limited, MuOx Limited and Summit Infectious Diseases Limited were dissolved.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 41 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| ANAND, Bhaskar | Director | 2024-04-17 | Jun 1977 | American |
| DUGGAN, Robert William | Director | 2019-12-24 | Apr 1944 | American |
| SONI, Manmeet Singh | Director | 2023-12-06 | Nov 1977 | American |
Show 41 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BENNING PRINCE, Sharon Jeen | Secretary | 2008-07-31 | 2008-11-17 |
| INNOCENT, Kenneth Ronald | Secretary | 2009-04-03 | 2010-01-20 |
| MILLINGTON, Darren Michael | Secretary | 2005-06-06 | 2008-07-31 |
| MONTGOMERY, John Alexander | Secretary | 2004-09-24 | 2005-06-06 |
| O'NEILL, Hugh Feargal | Secretary | 2020-06-30 | 2021-06-08 |
| SPENCER, Raymond John | Secretary | 2010-01-20 | 2014-09-03 |
| STRANGE, Melissa Claire | Secretary | 2014-09-03 | 2020-06-30 |
| WEIR, Anthony | Secretary | 2008-11-17 | 2009-03-23 |
| SWIFT INCORPORATIONS LIMITED | Corporate Nominee Secretary | 2004-08-04 | 2004-09-24 |
| ANDREWS, Valerie | Director | 2014-09-18 | 2019-10-11 |
| ARMSTRONG, Frank, Dr | Director | 2012-11-21 | 2019-12-24 |
| DAVIES, Stephen Graham, Professor | Director | 2013-11-22 | 2018-09-20 |
| DAVIES, Stephen Graham, Professor | Director | 2004-09-24 | 2013-02-28 |
| DHINGRA, Ankur | Director | 2022-08-18 | 2024-04-02 |
| EDWARDS, Glyn Owain | Director | 2012-04-04 | 2020-06-18 |
| ELLIOTT, George Reginald | Director | 2007-04-19 | 2012-11-21 |
| ERDTMANN, Rainer | Director | 2020-04-17 | 2020-11-11 |
| HAIR, Campbell | Director | 2021-12-06 | 2022-08-10 |
| LEE, Steven Koon Ching, Dr | Director | 2004-09-24 | 2010-12-03 |
| MAHATME, Ujwala | Director | 2020-07-13 | 2020-11-11 |
| MARANIAN, Jeffrey | Director | 2021-12-06 | 2022-01-21 |
| MELLON, James | Director | 2012-11-21 | 2014-12-03 |
| MILLINGTON, Darren Michael | Director | 2006-05-09 | 2008-09-19 |
| MONTGOMERY, John Alexander | Director | 2004-09-24 | 2006-09-26 |
| MULVANEY, Andrew William, Dr | Director | 2004-09-24 | 2005-10-07 |
| NORWOOD, David Robert | Director | 2004-09-29 | 2008-01-31 |
| POWELL, David Jonathan, Dr. | Director | 2021-01-29 | 2021-11-26 |
| PRICE, Barry John, Dr | Director | 2006-09-26 | 2018-09-20 |
| RICHARDS, Andrew John Mcglashan, Dr | Director | 2007-03-22 | 2012-11-21 |
| RICHARDS, Brian Mansel, Sir | Director | 2005-10-07 | 2008-01-31 |
| SONI, Manmeet Singh | Director | 2019-12-24 | 2020-11-11 |
| STEFANOV, Ventzislav Kirilov, Dr | Director | 2019-12-24 | 2020-12-04 |
| STORER, Richard, Dr | Director | 2006-04-26 | 2012-11-21 |
| STRACKER, Elaine Carla, Dr | Director | 2019-12-24 | 2020-06-25 |
| TAYLOR, James Christopher | Director | 2006-08-09 | 2008-01-31 |
| WALL, Colin David, Dr | Director | 2006-09-26 | 2009-01-22 |
| WEIR, Anthony | Director | 2008-11-17 | 2009-03-23 |
| WURZER, David Michael | Director | 2015-02-20 | 2019-12-24 |
| ZAMBELETTI, Leopoldo | Director | 2014-05-30 | 2019-12-24 |
| INSTANT COMPANIES LIMITED | Corporate Nominee Director | 2004-08-04 | 2004-09-24 |
| SWIFT INCORPORATIONS LIMITED | Corporate Nominee Director | 2004-08-04 | 2004-09-24 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Summit Therapeutics Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2020-09-18 | Active |
Filing timeline
Last 20 of 285 total filings
Material constitutional events — rename, articles re-file, resolution
- 2023-08-23 RESOLUTIONS Resolution
- 2023-06-10 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-10-22 | AA | accounts | Accounts with accounts type full | |
| 2025-09-19 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-11-08 | AA | accounts | Accounts with accounts type full | |
| 2024-10-03 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-04-26 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-25 | TM01 | officers | Termination director company with name termination date | |
| 2023-12-14 | AP01 | officers | Appoint person director company with name date | |
| 2023-10-02 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-08-23 | AA | accounts | Accounts with accounts type full | |
| 2023-08-23 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2023-08-23 | SH20 | capital | Legacy | |
| 2023-08-23 | CAP-SS | insolvency | Legacy | |
| 2023-08-23 | RESOLUTIONS | resolution | Resolution | |
| 2023-06-10 | RESOLUTIONS | resolution | Resolution | |
| 2023-05-31 | SH01 | capital | Capital allotment shares | |
| 2023-05-30 | SH01 | capital | Capital allotment shares | |
| 2022-10-04 | AA | accounts | Accounts with accounts type full | |
| 2022-09-20 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-08-19 | AP01 | officers | Appoint person director company with name date | |
| 2022-08-19 | TM01 | officers | Termination director company with name termination date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
-30.5%
£450,760 £313,283
-
Net assets
-83.2%
£3,624,595 £608,154
-
Employees
—
Not reported
-
Operating profit
+30.5%
-£4,360,213 -£3,030,985
-
Profit before tax
+30.5%
-£4,360,213 -£3,030,985
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers